Hims & Hers Stock Skyrockets 40% Following Landmark Weight-Loss Deal With Novo Nordisk

2026-03-09 companies

New York, Monday, 9 March 2026.
Ending a bitter legal feud, Novo Nordisk will now sell its blockbuster weight-loss medications through Hims & Hers, sending the telehealth platform’s stock soaring 40% in Monday trading.

From Courtroom Adversaries to Commercial Partners

The telehealth provider Hims & Hers Health, Inc. (NYSE: HIMS) and the Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) have officially transformed a contentious relationship into a collaborative distribution strategy [4][6]. Just last month, the dispute between the two entities had escalated into a formal legal battle [3][5]. The conflict centered on Hims & Hers offering compounded versions of semaglutide, the active ingredient in Novo Nordisk’s blockbuster diabetes and weight-loss medications, Ozempic and Wegovy [6]. Novo Nordisk vigorously sought to protect its branded products from these copycat medications, leading to a highly public feud [1][6].

Financial Fundamentals Drive Investor Optimism

Wall Street reacted aggressively to the news, sending shares of Hims & Hers surging 40% during Monday’s trading session [2]. Prior to the announcement, the stock had been trading near $15.74, meaning a 40% surge would mathematically push the valuation to approximately $22.036 per share [2][7]. The company boasts a solid financial foundation, carrying an enterprise value of about $4.45 billion and a price-to-earnings multiple of approximately 30.9 [7]. For the fiscal year 2024, Hims & Hers reported a robust revenue increase of 69%, maintaining a strong gross margin of roughly 69.7% and a net margin of about 5.5% [7].

A New Era for Direct-to-Consumer Healthcare

The integration of legacy pharmaceutical manufacturing with modern digital pharmacies represents a structural shift in healthcare delivery [GPT]. By leveraging the Hims & Hers online platform, Novo Nordisk secures a streamlined, direct-to-consumer channel for its highly coveted treatments [2][4]. While the strategic benefits are clear, the exact financial details of the commercial arrangement remain undisclosed [alert! ‘Details of the commercial arrangement were not disclosed in the Bloomberg report’] [6].

Sources

Pharmaceuticals Obesity drugs